MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction.
Jesper JensenMorten SchouCaroline KistorpJens FaberTine W HansenMagnus T JensenHenrik U AndersenPeter RossingTina VilsbøllPeter G JørgensenPublished in: Cardiovascular diabetology (2020)
Patients with T2D and HFpEF with high MR-proANP levels had an increased risk for CV events compared to patients with HFpEF without elevated MR-proANP and compared to patients without HF, supporting the use of MR-proANP in the definition of HFpEF from a prognostic point-of-view.